NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotech company focusing on cardiometabolic diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York.

Key points:

• President and CEO Hyung Heon Kim and CFO Marshall H. Woodworth will present a company overview on September 10 at 1:30 pm ET.
• Management will be available for one-on-one meetings during the conference.
• Institutional investors can register at www.hcwevents.com/annualconference to access the presentation or request meetings.
• For meetings outside the conference, investors can contact Michael Miller at mmiller@rxir.com.

CAMBRIDGE, Mass., Sept. 3, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview on Tuesday, September 10, at 1:30 pm ET, during the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York.

Management will also be available for one-on-one meetings during the event. Institutional investors who would like to listen to the Company's presentation or request a meeting can do so after registering for the conference at www.hcwevents.com/annualconference. To schedule a meeting with management outside of the conference, investors can contact Michael Miller at mmiller@rxir.com.

About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visit www.neurobopharma.com.

Contacts:

NeuroBo Pharmaceuticals, Inc.
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com  

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

View original content:https://www.prnewswire.com/news-releases/neurobo-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302236111.html

SOURCE NeuroBo Pharmaceuticals, Inc.

FAQ

When is NeuroBo Pharmaceuticals (NRBO) presenting at the H.C. Wainwright Global Investment Conference?

NeuroBo Pharmaceuticals (NRBO) is presenting on Tuesday, September 10, 2024, at 1:30 pm ET during the H.C. Wainwright 26th Annual Global Investment Conference.

Who will be representing NeuroBo Pharmaceuticals (NRBO) at the H.C. Wainwright conference?

Hyung Heon Kim, President and Chief Executive Officer, and Marshall H. Woodworth, Chief Financial Officer, will be representing NeuroBo Pharmaceuticals (NRBO) at the conference.

How can investors arrange meetings with NeuroBo Pharmaceuticals (NRBO) management during the conference?

Institutional investors can register at www.hcwevents.com/annualconference to request meetings with NeuroBo Pharmaceuticals (NRBO) management during the conference.

What is the focus area of NeuroBo Pharmaceuticals (NRBO)?

NeuroBo Pharmaceuticals (NRBO) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases.

How can investors contact NeuroBo Pharmaceuticals (NRBO) for meetings outside the conference?

Investors can contact Michael Miller at mmiller@rxir.com to schedule meetings with NeuroBo Pharmaceuticals (NRBO) management outside of the conference.